Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine

Asahito Hama, Yoshiyuki Takahashi, Hideki Muramatsu, Masafumi Ito, Atsushi Narita, Yoshiyuki Kosaka, Masahiro Tsuchida, Ryoji Kobayashi, Etsuro Ito, Hiromasa Yabe, Shouichi Ohga, Akira Ohara, Seiji Kojima

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The 2008 World Health Organization classification proposed a new entity in childhood myelodysplastic syndrome, refractory cytopenia of childhood. However, it is unclear whether this morphological classification reflects clinical outcomes. We retrospectively reviewed bone marrow morphology in 186 children (median age 8 years; range 1-16 years) who were enrolled in the prospective study and received horse antithymocyte globulin and cyclosporine between July 1999 and November 2008. The median follow-up period was 87 months (range 1-146 months). Out of 186 patients, 62 (33%) were classified with aplastic anemia, 94 (49%) with refractory cytopenia of childhood, and 34 (18%) with refractory cytopenia with multilineage dysplasia. Aplastic anemia patients received granulocyte colony-stimulating factor more frequently and for longer durations than other patients (P<0.01). After six months, response rates to immunosuppressive therapy were not significantly different among the 3 groups. Acquisition of chromosomal abnormalities was observed in 5 patients with aplastic anemia, 4 patients with refractory cytopenia of childhood, and 3 patients with refractory cytopenia with multilineage dysplasia. Although the cumulative incidence of total clonal evolution at ten years was not significantly different among the 3 groups, the cumulative incidence of monosomy 7 development was significantly higher in aplastic anemia than in the other groups (P=0.02). Multivariate analysis revealed that only granulocyte colony-stimulating factor administration duration of 40 days or more was a significant risk factor for monosomy 7 development (P=0.02). These findings suggest that even the introduction of a strict morphological distinction from hypoplastic myelodysplastic syndrome cannot eradicate clonal evolution in children with aplastic anemia.

Original languageEnglish
Pages (from-to)1426-1433
Number of pages8
JournalHaematologica
Volume100
Issue number11
DOIs
Publication statusPublished - Oct 31 2015

Fingerprint

Antilymphocyte Serum
Aplastic Anemia
Immunosuppressive Agents
Cyclosporine
Clonal Evolution
Myelodysplastic Syndromes
Granulocyte Colony-Stimulating Factor
Therapeutics
Incidence
Chromosome Aberrations
Horses
Multivariate Analysis
Bone Marrow
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine. / Hama, Asahito; Takahashi, Yoshiyuki; Muramatsu, Hideki; Ito, Masafumi; Narita, Atsushi; Kosaka, Yoshiyuki; Tsuchida, Masahiro; Kobayashi, Ryoji; Ito, Etsuro; Yabe, Hiromasa; Ohga, Shouichi; Ohara, Akira; Kojima, Seiji.

In: Haematologica, Vol. 100, No. 11, 31.10.2015, p. 1426-1433.

Research output: Contribution to journalArticle

Hama, A, Takahashi, Y, Muramatsu, H, Ito, M, Narita, A, Kosaka, Y, Tsuchida, M, Kobayashi, R, Ito, E, Yabe, H, Ohga, S, Ohara, A & Kojima, S 2015, 'Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine', Haematologica, vol. 100, no. 11, pp. 1426-1433. https://doi.org/10.3324/haematol.2015.128553
Hama, Asahito ; Takahashi, Yoshiyuki ; Muramatsu, Hideki ; Ito, Masafumi ; Narita, Atsushi ; Kosaka, Yoshiyuki ; Tsuchida, Masahiro ; Kobayashi, Ryoji ; Ito, Etsuro ; Yabe, Hiromasa ; Ohga, Shouichi ; Ohara, Akira ; Kojima, Seiji. / Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine. In: Haematologica. 2015 ; Vol. 100, No. 11. pp. 1426-1433.
@article{65483182d3d34371beb935f8f9277a25,
title = "Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine",
abstract = "The 2008 World Health Organization classification proposed a new entity in childhood myelodysplastic syndrome, refractory cytopenia of childhood. However, it is unclear whether this morphological classification reflects clinical outcomes. We retrospectively reviewed bone marrow morphology in 186 children (median age 8 years; range 1-16 years) who were enrolled in the prospective study and received horse antithymocyte globulin and cyclosporine between July 1999 and November 2008. The median follow-up period was 87 months (range 1-146 months). Out of 186 patients, 62 (33{\%}) were classified with aplastic anemia, 94 (49{\%}) with refractory cytopenia of childhood, and 34 (18{\%}) with refractory cytopenia with multilineage dysplasia. Aplastic anemia patients received granulocyte colony-stimulating factor more frequently and for longer durations than other patients (P<0.01). After six months, response rates to immunosuppressive therapy were not significantly different among the 3 groups. Acquisition of chromosomal abnormalities was observed in 5 patients with aplastic anemia, 4 patients with refractory cytopenia of childhood, and 3 patients with refractory cytopenia with multilineage dysplasia. Although the cumulative incidence of total clonal evolution at ten years was not significantly different among the 3 groups, the cumulative incidence of monosomy 7 development was significantly higher in aplastic anemia than in the other groups (P=0.02). Multivariate analysis revealed that only granulocyte colony-stimulating factor administration duration of 40 days or more was a significant risk factor for monosomy 7 development (P=0.02). These findings suggest that even the introduction of a strict morphological distinction from hypoplastic myelodysplastic syndrome cannot eradicate clonal evolution in children with aplastic anemia.",
author = "Asahito Hama and Yoshiyuki Takahashi and Hideki Muramatsu and Masafumi Ito and Atsushi Narita and Yoshiyuki Kosaka and Masahiro Tsuchida and Ryoji Kobayashi and Etsuro Ito and Hiromasa Yabe and Shouichi Ohga and Akira Ohara and Seiji Kojima",
year = "2015",
month = "10",
day = "31",
doi = "10.3324/haematol.2015.128553",
language = "English",
volume = "100",
pages = "1426--1433",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "11",

}

TY - JOUR

T1 - Comparison of long-term outcomes between children with aplastic anemia and refractory cytopenia of childhood who received immunosuppressive therapy with antithymocyte globulin and cyclosporine

AU - Hama, Asahito

AU - Takahashi, Yoshiyuki

AU - Muramatsu, Hideki

AU - Ito, Masafumi

AU - Narita, Atsushi

AU - Kosaka, Yoshiyuki

AU - Tsuchida, Masahiro

AU - Kobayashi, Ryoji

AU - Ito, Etsuro

AU - Yabe, Hiromasa

AU - Ohga, Shouichi

AU - Ohara, Akira

AU - Kojima, Seiji

PY - 2015/10/31

Y1 - 2015/10/31

N2 - The 2008 World Health Organization classification proposed a new entity in childhood myelodysplastic syndrome, refractory cytopenia of childhood. However, it is unclear whether this morphological classification reflects clinical outcomes. We retrospectively reviewed bone marrow morphology in 186 children (median age 8 years; range 1-16 years) who were enrolled in the prospective study and received horse antithymocyte globulin and cyclosporine between July 1999 and November 2008. The median follow-up period was 87 months (range 1-146 months). Out of 186 patients, 62 (33%) were classified with aplastic anemia, 94 (49%) with refractory cytopenia of childhood, and 34 (18%) with refractory cytopenia with multilineage dysplasia. Aplastic anemia patients received granulocyte colony-stimulating factor more frequently and for longer durations than other patients (P<0.01). After six months, response rates to immunosuppressive therapy were not significantly different among the 3 groups. Acquisition of chromosomal abnormalities was observed in 5 patients with aplastic anemia, 4 patients with refractory cytopenia of childhood, and 3 patients with refractory cytopenia with multilineage dysplasia. Although the cumulative incidence of total clonal evolution at ten years was not significantly different among the 3 groups, the cumulative incidence of monosomy 7 development was significantly higher in aplastic anemia than in the other groups (P=0.02). Multivariate analysis revealed that only granulocyte colony-stimulating factor administration duration of 40 days or more was a significant risk factor for monosomy 7 development (P=0.02). These findings suggest that even the introduction of a strict morphological distinction from hypoplastic myelodysplastic syndrome cannot eradicate clonal evolution in children with aplastic anemia.

AB - The 2008 World Health Organization classification proposed a new entity in childhood myelodysplastic syndrome, refractory cytopenia of childhood. However, it is unclear whether this morphological classification reflects clinical outcomes. We retrospectively reviewed bone marrow morphology in 186 children (median age 8 years; range 1-16 years) who were enrolled in the prospective study and received horse antithymocyte globulin and cyclosporine between July 1999 and November 2008. The median follow-up period was 87 months (range 1-146 months). Out of 186 patients, 62 (33%) were classified with aplastic anemia, 94 (49%) with refractory cytopenia of childhood, and 34 (18%) with refractory cytopenia with multilineage dysplasia. Aplastic anemia patients received granulocyte colony-stimulating factor more frequently and for longer durations than other patients (P<0.01). After six months, response rates to immunosuppressive therapy were not significantly different among the 3 groups. Acquisition of chromosomal abnormalities was observed in 5 patients with aplastic anemia, 4 patients with refractory cytopenia of childhood, and 3 patients with refractory cytopenia with multilineage dysplasia. Although the cumulative incidence of total clonal evolution at ten years was not significantly different among the 3 groups, the cumulative incidence of monosomy 7 development was significantly higher in aplastic anemia than in the other groups (P=0.02). Multivariate analysis revealed that only granulocyte colony-stimulating factor administration duration of 40 days or more was a significant risk factor for monosomy 7 development (P=0.02). These findings suggest that even the introduction of a strict morphological distinction from hypoplastic myelodysplastic syndrome cannot eradicate clonal evolution in children with aplastic anemia.

UR - http://www.scopus.com/inward/record.url?scp=84946234595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946234595&partnerID=8YFLogxK

U2 - 10.3324/haematol.2015.128553

DO - 10.3324/haematol.2015.128553

M3 - Article

C2 - 26273061

AN - SCOPUS:84946234595

VL - 100

SP - 1426

EP - 1433

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 11

ER -